PharmaCyte Biotech PMCB

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
Today's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

PharmaCyte Biotech (PMCB) Business Model and Operations Summary
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Key Insights

PharmaCyte Biotech (PMCB) Core Market Data and Business Metrics
  • Latest Closing Price

    $1.14
  • Market Cap

    $7.21 Million
  • Total Outstanding Shares

    6.86 Million Shares
  • Total Employees

    2
  • IPO Date

    September 11, 2003
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Headquarters

    23046 Avenida De La Carlota, Suite 600, Laguna Hills, CA, 92653

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Short Interest

Short Interest

This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.

Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.

Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.

Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.

Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.

Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Historical Stock Splits

Execution DateSplit Amount

Historical Dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about PMCB from trusted financial sources